Susan Galbraith, MD PhD, is is Executive Vice President and Head of Oncology Research & Development from initial discovery through late-stage development at AstraZeneca in Cambridge, UK.

A clinical oncologist by education, she has over 20 years of experience in drug discovery and development. Her approach has successfully led to the development of four new cancer drugs, now approved worldwide. Among them, two have established themselves as first-in-class drugs for lung cancer (NSCLC, osimetrinib) and advanced ovarian cancer (olaparib). She is an advocate for diversity and inclusion and actively acts as a mentor to promote the career advancement of young female researchers.

She is a Fellow of the Academy of Medical Sciences, and was elected to the Board of Directors of the American Association for Cancer Research in 2021.